Dr Fawad Ur Rehman joined CRM in November 2021 as a postdoctoral fellow. He is part of the Grand Challenge Fund (GCF) project that aims to develop novel gene-editing therapies for β-thalassemia and sickle cell anaemia. Dr Fawad specialises in nanomedicine and nano-drug delivery systems. Before joining CRM, he was a senior postdoctoral fellow at Henan -MQ University International Joint Center for Biomedical Innovation, Henan University, Kaifeng, China, and a postdoctoral researcher at ZhongDa Hospital, affiliated with Medical School of Southeast University, Nanjing, China.
With a PhD in Biomedical Engineering from the Southeast University, Nanjing, China, Dr Fawad has more than 50 publications to his credit. Three of his patents have been accepted, and one is under review.